| |

Over Forty Clinical Trials for Mesothelioma

ByAlex Strauss

12131629_Researcher

Mesothelioma is still a difficult cancer to treat. Today, there are at least 42 active clinical trials for mesothelioma, each trying to demonstrate a better treatment outcome than standard therapies. While there are still trials of chemotherapy, radiation and surgery, today the emphasis is on newer therapies that can better target the tumor cells instead of indiscriminately harming cancer and healthy cells alike. These better targeted therapies go by different names depending on the type and include terms like: anti-cytokine, antiangiogenesis, enzyme inhibitor therapy, kinase inhibitor therapy, gene therapy, biological therapy, and immune therapy.

As of March 2009 there were at least sixteen trials of these newer therapies plus eight combination regimes of a newer therapy and chemotherapy and another trial with radiation therapy. These newer therapies include treatments designed to inhibit tumor cell surface receptors (like Dasatinib, Imatinib, Sorafenib), treatments that inhibit growth factor receptors (like Vandetanib and Bevacizumab), antibodies (like MORAb-009 and SS1(dsFv)-PE38 immunotoxin), and proteasome inhibitors (like Bortezomib).

Below is a list of some of the clinical trials being offered for mesothelioma. You are urged to check the National Cancer Institute website for the most current list. It is available here: http://www.cancer.gov/clinicaltrials/search

Newer Therapies

Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Phase II Study of Sunitinib Malate in Patients With Advanced Malignant Pleural Mesothelioma

Phase II Study of Dasatinib in Patients With Previously Treated Malignant Mesothelioma

Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Mesothelioma

Phase II Study of Bortezomib in Patients With Malignant Pleural Mesothelioma

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma

Phase II Study of Everolimus in Patients With Unresectable Malignant Pleural Mesothelioma

Sorafenib in Previously Treated Malignant Mesothelioma

Dasatinib in Resectable Malignant Pleural Mesothelioma

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Phase I Study of FR901228 (Depsipeptide) and Flavopiridol in Patients With Advanced Primary Lung or Esophageal Cancer, Malignant Pleural Mesothelioma, or Lung or Pleural Metastases

Newer Therapy + Chemotherapy

Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Phase II Study of Bortezomib and Cisplatin as First-Line Treatment in Patients With Malignant Mesothelioma

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Combination With Pemetrexed Disodium and Cisplatin in Patients With Unresectable Malignant Epithelial Pleural Mesothelioma

Chemotherapy

Mesothelioma Avastin Plus Pemetrexed-Cisplatin Study Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM

Phase II Study of Pemetrexed Disodium, Cisplatin, and Vitamin B12 in Patients With Unresectable Pleural Mesothelioma

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects with Pulmonary and Pleural Malignancies

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Surgery

Phase III Randomized Study of Video-Assisted Thoracoscopic Cytoreductive Pleurectomy Versus Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma

Surgery + Chemotherapy

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Radiation

Short Neoadjuvant Hemithoracic IMRT for MPM

Tomotherapy Treatment for Mesothelioma

Chemotherapy + Radiation

Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma

Newer Therapy + Radiation

Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Surgery + Chemotherapy + Radiation

Phase II Randomized Study of Neoadjuvant Therapy With Pemetrexed Disodium and Cisplatin Followed By Extrapleural Pneumonectomy With or Without Postoperative Hemithoracic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Randomized Pilot Study of Neoadjuvant Combination Chemotherapy With Versus Without Surgery and Adjuvant Radiotherapy in Patients With Resectable Malignant Mesothelioma

Gene Therapy

Gene Therapy for Pleural Malignancies

Immune Therapy

Dendritic Cell-Based Immunotherapy in Mesothelioma

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…